- Aims: to document the efficacy and safety outcomes of SCS in persons with chronic, chemotherapy-induced peripheral neuropathy
- Types of chemotherapy: Taxotere, Oxaliplatin, Paclitaxel
- Primary outcome measure: % responder rate at six months
- Number of participants: 20-25
- Follow-up: 12 months